Cannabis-derived CBD's growing therapeutic use faces a potential cardiac safety concern that could affect millions of users. New molecular research reveals the compound directly interferes with potassium channels essential for normal heart rhythm regulation, using two different blocking mechanisms that could predispose users to dangerous arrhythmias. The investigation focused on KV7.1 channels, which control the heart's electrical repolarization phase between beats. Researchers discovered CBD inhibits both the standalone KV7.1 channel and its complex with the KCNE1 regulatory protein through completely separate binding sites and mechanisms. The standalone channel showed different sensitivity patterns compared to the physiologically relevant KV7.1/KCNE1 complex that actually operates in human cardiac tissue. This dual-target activity suggests CBD's cardiac effects may be more complex than previously understood. The findings add crucial context to CBD's rapidly expanding clinical applications, from epilepsy treatment to anxiety management. While therapeutic CBD doses vary widely across conditions, this research identifies a previously unrecognized mechanism that could contribute to cardiovascular side effects reported in some users. The discovery is particularly relevant given that potassium channel dysfunction underlies several inherited cardiac arrhythmia syndromes, and drug-induced channel blockade has historically been a major cause of medication withdrawals from market. However, the clinical significance remains unclear without dose-response data and correlation with actual cardiac events. This represents foundational mechanistic research that should inform future safety studies and dosing guidelines, especially for patients with existing cardiac conditions or those taking medications affecting heart rhythm.